Cognition Therapeutics Awarded $2.14 Million in Supplemental Grant Funding from NIA to Support SEQUEL Clinical Trial
27 sept. 2022 07h32 HE
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX) announced today that the company has received a $2.14M grant award from the National Institute on...
Cognition Therapeutics Announces Participation in September Investment Conferences
06 sept. 2022 07h32 HE
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX) (the “Company” or “Cognition”), a clinical-stage biopharmaceutical company engaged in the discovery...
Cognition Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
09 août 2022 07h00 HE
|
Cognition Therapeutics, Inc.
Ongoing Patient Dosing in SHIMMER Study for DLB and SHINE Study for Alzheimer’s DiseasePositive Preliminary Data for Dry AMD Program Presented at ARVO 2022Proteomics Data from SPARC read out at AAIC ...
Cognition Therapeutics Presents New Proteomic Data on Effect of CT1812 Treatment on Normalization of Disrupted Alzheimer’s Disease Processes
04 août 2022 16h02 HE
|
Cognition Therapeutics, Inc.
NEW YORK, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX) announced that Mary Hamby, Ph.D., vice president of research, presented results at the at Alzheimer’s...
Cognition Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022
03 août 2022 16h05 HE
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative,...
Cognition Therapeutics Presenting New Analyses from Ongoing Clinical Trial of CT1812 in Mild-to-Moderate Alzheimer’s Disease
19 juil. 2022 08h00 HE
|
Cognition Therapeutics, Inc.
- Analyses Demonstrate CT1812 Impact on Alzheimer’s Disease Processes - NEW YORK, July 19, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX) will be in attendance at the 2022...
Cognition Therapeutics Doses First Patient with Dementia with Lewy Bodies in Phase 2 Clinical Study of CT1812
23 juin 2022 07h30 HE
|
Cognition Therapeutics, Inc.
- Study Supported by $30M NIA Grant Award and Conducted in Collaboration with University of Miami Miller School of Medicine and the Lewy Body Dementia Association - NEW YORK, June 23, 2022 (GLOBE...
Cognition Therapeutics Announces Presentation at the Upcoming JMP Securities Life Sciences Conference
08 juin 2022 07h30 HE
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., June 08, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX) announced that the company will participate in the JMP Securities Life Sciences Conference on June 16th....
Cognition Therapeutics to Host Virtual KOL Symposium on Dry Age-related Macular Degeneration and the Potential for Sigma-2 Modulation
02 juin 2022 16h01 HE
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., June 02, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), announced plans to hold a virtual KOL symposium on June 9, 2022, from 10:00 - 11:30 a.m. ET to discuss...
Cognition Therapeutics to Participate in H.C. Wainwright Global Investment Conference
13 mai 2022 07h30 HE
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., May 13, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage neuroscience company developing therapies that treat age-related degenerative diseases...